COMP <GO>
RVMD vs ABBV // GROSS PROFIT MARGIN
Revolution Medicines Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: RVMD 5
— ABBV 9
▲ GROSS PROFIT MARGIN LEADER: ABBV
LAST: $191.31 (+0.55%) • MKT CAP: $40.78B
gross-margins
44.00%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
gross-margins
70.20%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RVMD VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RVMD | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 44.00% | 70.20% | -26.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -28.60% | 29.00% | -57.60 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.24% | 3.47% | -5.71 | ABBV | /fcf-yield <GO> |
| Operating Margin | 16.50% | 24.60% | -8.10 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 12.40% | 6.90% | +5.50 | RVMD | /net-margins <GO> |
| Revenue Growth (YoY) | 15.40% | 8.60% | +6.80 | RVMD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 5.33 | +20.67 | RVMD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 7.40% | -0.30 | RVMD | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.8 | 72.8 | -24.03 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.07 | 1.15 | -0.08 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 34.0x | 113.1x | -79.10 | RVMD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $40.78B | $513.86B | -$473.08B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RVMD REV | ABBV REV | RVMD GROSS % | ABBV GROSS % | RVMD FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $61.16B | — | 70.2% | -$913.7M | $17.82B |
| FY 2024 | $0 | $56.33B | — | 70.0% | -$567.7M | $17.83B |
| FY 2023 | $11.6M | $54.32B | 44.0% | 44.0% | -$351.1M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RVMD // BETA 1.07
ABBV // BETA 1.15